This is consistent with our finding that of the 29/34 patient aspirates responding to SAR442257, and the most promising biomarker of response was high CD38 expression on multiple myeloma cells relative to surrounding non-MM cells. The gene discussed is CD38; the disease is Miyoshi myopathy.